Joshi Poonam, Joshi Amit, Prabhash Kumar, Noronha Vanita, Chaturvedi Pankaj
Department of Head and Neck Surgery, Tata Memorial Hospital, Mumbai, Maharashtra, India.
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
Indian J Med Paediatr Oncol. 2015 Oct-Dec;36(4):249-54. doi: 10.4103/0971-5851.171548.
Head and neck cancer is the third most common cancer in India with 60% presenting in advanced stages. There is the emerging role of neoadjuvant chemotherapy (NACT) in the management of these advanced cancers. There is a general perception that complication rates are higher with the use of NACT.
This is a retrospectively collected data of head and neck cancer patients operated at our hospital from March 2013 to September 2014. A total of 205 patients were included in the study. These patients were studied in two groups. Group 1 included 153 patients who underwent surgery alone, and Group 2 included 52 patients who received 2-3 cycles of NACT followed by surgery.
The mean age of the population was 51 years in the Group 1 and 45 years in Group 2. The hospital stay and readmissions in postoperative period were similar in the two groups. In this study, the complication rate was 37.9% in the surgery patients and 30.8% in the NACT patients (P = 0.424).
The postoperative complication rates in patients who received NACT followed by surgery were not significantly different from those who underwent surgery.
头颈癌是印度第三大常见癌症,60%的患者就诊时已处于晚期。新辅助化疗(NACT)在这些晚期癌症的治疗中发挥着越来越重要的作用。人们普遍认为使用NACT会使并发症发生率更高。
这是一项对2013年3月至2014年9月在我院接受手术的头颈癌患者进行回顾性收集的数据。共有205名患者纳入研究。这些患者被分为两组。第1组包括153例仅接受手术的患者,第2组包括52例接受2 - 3个周期新辅助化疗后再行手术的患者。
第1组患者的平均年龄为51岁,第2组为45岁。两组患者的住院时间和术后再入院情况相似。在本研究中,单纯手术患者的并发症发生率为37.9%,新辅助化疗患者的并发症发生率为30.8%(P = 0.424)。
接受新辅助化疗后再行手术的患者术后并发症发生率与单纯接受手术的患者无显著差异。